|1.||Polis, Adam B: 9 articles (07/2006 - 01/2002)|
|2.||Geba, Gregory P: 9 articles (02/2006 - 01/2002)|
|3.||Dhir, Ashish: 8 articles (12/2009 - 12/2005)|
|4.||Derry, Sheena: 7 articles (01/2013 - 01/2005)|
|5.||Moore, R Andrew: 7 articles (01/2013 - 01/2005)|
|6.||Solomon, Daniel H: 7 articles (12/2009 - 04/2002)|
|7.||Petruschke, Richard A: 7 articles (08/2007 - 05/2004)|
|8.||Kulkarni, Shrinivas K: 7 articles (01/2007 - 06/2002)|
|9.||Whelton, Andrew: 7 articles (05/2006 - 06/2002)|
|10.||Burke, Thomas A: 7 articles (02/2004 - 03/2002)|
12/01/2001 - "Twenty-five milligrams rofecoxib given once a day at midday showed the same remarkable improvement in pain at night, pain at rest, and pain induced by exercise. "
01/01/2001 - "Rofecoxib was considered by patients to be a very effective treatment for OA, with satisfaction scores of good or very good in the domains of pain, mobility and general satisfaction. "
01/01/2007 - "H/A (p = 0.003), but not rofecoxib (p = 0.256) was significantly more effective than placebo for total pain relief at 6 h (TOPAR6). "
03/01/2006 - "Compared with placebo, perioperative administration of rofecoxib 50 mg provided significant opioid sparing, significantly better pain control, improved clinical outcomes, and was well tolerated."
11/01/2005 - "Previous data have demonstrated that rofecoxib has good analgesic efficacy for acute postoperative dental pain. "
09/01/1999 - "No significant inhibition of cyclo-oxygenase-1 is observed with rofecoxib up to doses of 1000 mg. In 4 large double-blind randomised trials performed in patients with osteoarthritis, rofecoxib 12.5 and 25 mg/day significantly improved physical functioning, assessed using the Western Ontario and McMasters Universities Osteoarthritis Index and patient or investigator global assessment, compared with placebo. "
04/01/2001 - "A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis."
11/01/2004 - "Fifty-three outpatients, men and women (mean age: 64 years; SD+/-9.5), with symptomatic osteoarthritis of hip or knee were included in an open label study with rofecoxib. "
01/01/2003 - "Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study."
01/01/2003 - "This study conducted in conditions close to daily practice confirms that the use of rofecoxib is associated with a low rate of serious adverse events in patients with osteoarthritis."
04/01/2004 - "Rofecoxib (50 mg per os), given before and after surgery, was effective in improving postoperative pain management, as well as the speed and quality of recovery after outpatient inguinal herniorrhaphy. "
07/01/2003 - "An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management."
01/01/2009 - "Randomised, double blind, placebo-controlled trials of single dose orally administered rofecoxib in adults with moderate to severe acute postoperative pain. "
01/01/2005 - "Randomised controlled trials of adult patients who received either rofecoxib or placebo for postoperative pain. "
01/01/2004 - "Randomised controlled trials of adult patients who received either rofecoxib or placebo for postoperative pain. "
01/01/2005 - "This study is indicative of an anti-angiogenic efficacy of continuous low-dose TMZ plus rofecoxib in GBMs, especially in those tumors that are characterized by a high angiogenic activity."
01/01/2005 - "Clinically relevant doses of the COX-2 inhibitor rofecoxib given orally were effective in inhibiting the growth of small (but not large) tumors in 3 murine NSCLC cell lines tested and in preventing recurrences after surgical debulking. "
01/01/2011 - "Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial."
01/01/2005 - "To study rofecoxib as adjuvant therapy, large established tumors (14-18 days after tumor inoculation) were surgically debulked and animals were treated with rofecoxib starting 3 days before surgery. "
02/01/2003 - "In a clinical study, we analyzed the effect of a selective COX-2 inhibitor, Rofecoxib, on the migration of monocytes derived from cancer patients. "
12/01/2009 - "We identified a cohort of 33 045 patients with arthritis and chronic use of any selective Cox-2 inhibitor during the 6 months before the withdrawal of rofecoxib in claims data from several US health plans. "
02/02/2008 - "When CJ-042,794 and rofecoxib were administered to adjuvant-induced arthritis rats on Days 12-22 twice daily, both compounds reversed paw swelling to normal levels. "
06/01/2006 - "Half (53.0%) had used a coxib for arthritis; 277 (28.6%) had used rofecoxib. "
12/01/2004 - "The news that Vioxx was pulled from the market rattled me, since I had been taking it for my arthritis for almost two years. "
10/18/2004 - "Painful withdrawal for makers of Vioxx: pulling of arthritis drug raises questions on marketing, safety risks."
|4.||Cyclooxygenase 2 (Cyclooxygenase-2)
|6.||Diclofenac (SR 38)
|10.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|2.||Oral Surgery (Maxillofacial Surgery)
|3.||Drug Therapy (Chemotherapy)
|5.||Ambulatory Surgical Procedures (Outpatient Surgery)